Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
Kevin Griffis brought his experience in government and politics to Planned Parenthood at the perfect time, leading the fight to protect birth control coverage under the Trump administration and destigmatizing abortion.
It turns out the real goal is going after Washington's favorite whipping boy — high drug prices.
Although it's a long way from the president's desk, the Tax Cut and Jobs Act of 2017 contains plenty of good news for the life sciences industry and its marketing partners.
The first year of the Trump administration was kind to pharma, but it might not be so fortunate in 2018.
Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
Do you recall what President Trump tweeted right after Merck's Kenneth Frazier resigned from his American Manufacturing Council?
Merck CEO Kenneth Frazier's exit from a presidential manufacturing council may go down as one of the most principled stands by the CEO of a major U.S. company, let alone a drugmaker.
It's not often that pharmaceutical companies are held up as examples of morality or leadership to the general public.
That's why the Coalition for Healthcare Communication is focused on creating self-regulatory guidelines.
Merck CEO leaves Trump's manufacturing council over Charlottesville response; researchers struggle to fill clinical trials for IO drugs; Roche shareholders sue over top-line results
Trump administration considers outcomes-based approach to lower drug prices; Sanofi to acquire vaccines biotech; Nestle partners with Enterome to develop microbiome-based diagnostics
Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
50% of consumers say they will share their health data with tech giants; pharma CEOs expect pricing proposal from Trump administration; FDA approves generic versions of Strattera
In short, he'll be further along the learning curve than anyone ever tapped for the nation's number-one public health regulatory slot.
Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported
Despite budgets bouncing back from a decrease in 2015, big threats have appeared that may temper future plans, Iskowitz writes.
In short, the Trump team, I predict, will seek to tweak FDA.
Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Last week President Trump told drugmakers that 'the pricing has been astronomical.'
It's hard to be against the concept of reform, but Trump is better known for epithets than policy details, Kamp writes.
A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.